D. Rodriguez-abreu, A. Bordoni, and E. Zucca, Epidemiology of hematological malignancies, Ann Oncol, vol.18, issue.1, pp.3-8, 2007.

O. Visser, A. Trama, and M. Maynadié, Incidence, survival and prevalence of myeloid malignancies in Europe, Eur J Cancer, vol.48, issue.17, pp.3257-3266, 2012.

H. Döhner, E. H. Estey, and S. Amadori, Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet, Blood, vol.115, issue.3, pp.453-474, 2010.

A. Shah, T. Andersson, B. Rachet, M. Björkholm, and P. C. Lambert, Survival and cure of acute myeloid leukaemia in England, 1971-2006: a population-based study, Br J Haematol, vol.162, issue.4, pp.509-516, 2013.

L. J. Lu and K. Randerath, Long term instability and molecular mechanism of 5-azacytidine-induced DNA hypomethylation in normal and neoplastic tissues in vivo, Mol Pharmacol, vol.26, issue.3, pp.594-603, 1984.

C. Stresemann and F. Lyko, Modes of action of the DNA Methyltransferase inhibitors azacytidine and decitabine, Int J Cancer, vol.123, issue.1, pp.8-13, 2008.

M. Karahoca and R. L. Momparler, Pharmacokinetic and pharmacodynamic analysis of 5-aza-2?-deoxycytidine (decitabine) in the design of its doseschedule for cancer therapy, Clin Epigenetics, vol.5, issue.1, p.3, 2013.

W. Blum, R. Garzon, and R. B. Klisovic, Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine, Proc Natl Acad Sci, vol.107, issue.16, pp.7473-7478, 2010.

J. E. Lancet, J. E. Cortes, and D. E. Hogge, Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML, Blood, vol.123, issue.21, pp.3239-3246, 2014.

J. E. Lancet, G. L. Uy, and J. E. Cortes, Final results of a phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AML, J Clin Oncol, vol.34, issue.15_suppl, pp.7000-7000, 2016.

E. A. Griffiths, G. Choy, S. Redkar, P. Taverna, M. Azab et al., SGI-110: DNA methyltransferase inhibitor oncolytic, Drugs Future, vol.38, issue.8, pp.535-543, 2013.

S. Vijayaraghavalu and V. Labhasetwar, Efficacy of decitabine-loaded nanogels in overcoming cancer drug resistance is mediated via sustained DNA methyltransferase 1 (DNMT1) depletion, Cancer Lett, vol.331, issue.1, pp.122-129, 2013.

B. Heurtault, P. Saulnier, B. Pech, J. Proust, and J. Benoit, A novel phase inversion-based process for the preparation of lipid nanocarriers, Pharm Res, vol.19, issue.6, pp.875-880, 2002.

N. T. Huynh, C. Passirani, P. Saulnier, and J. P. Benoit, Lipid nanocapsules: a new platform for nanomedicine, Int J Pharm, vol.379, issue.2, pp.201-209, 2009.

F. Lagarce and C. Passirani, Nucleic-acid delivery using lipid nanocapsules, Curr Pharm Biotechnol, vol.17, issue.8, pp.723-727, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01392476

J. Hureaux, F. Lagarce, and F. Gagnadoux, Toxicological study and efficacy of blank and paclitaxel-loaded lipid nanocapsules after i.v. administration in mice, Pharm Res, vol.27, issue.3, pp.421-430, 2010.

J. Hureaux, F. Lacoeuille, and F. Lagarce, Absence of lung fibrosis after a single pulmonary delivery of lipid nanocapsules in rats, Int J Nanomedicine, vol.12, pp.8159-8170, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-01813483

O. Thomas and F. Lagarce, Lipid nanocapsules: a nanocarrier suitable for scale-up process, J Drug Delivery Sci Technol, vol.23, issue.6, pp.555-559, 2013.

T. Briot, E. Roger, N. Lautram, A. Verger, A. Clavreul et al., Development and in vitro evaluations of new decitabine nanocarriers for the treatment of acute myeloid leukemia, Int J Nanomedicine, vol.12, pp.8427-8442, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-01668530

H. M. Kantarjian, X. G. Thomas, and A. Dmoszynska, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia, JCO, vol.30, issue.21, pp.2670-2677, 2012.

K. T. Lin, R. L. Momparler, and G. E. Rivard, High-performance liquid chromatographic analysis of chemical stability of 5-aza-2?-deoxycytidine, J Pharm Sci, vol.70, issue.11, pp.1228-1232, 1981.

H. Tománková and J. Zýka, Study of the time dependence of the stability of 5-aza-2?-deoxycytidine in acid medium, vol.25, pp.281-288

K. Sun, H. , H. Rita, M. Krämer, and I. , Physicochemical stability of reconstituted decitabine (Dacogen®) solutions and ready-to-administer infusion bags when stored refrigerated or frozen, Pharmaceutical Technology in Hospital Pharmacy, vol.22017, p.145

J. Hureaux, F. Lagarce, and F. Gagnadoux, Lipid nanocapsules: readyto-use nanovectors for the aerosol delivery of paclitaxel, Eur J Pharm Biopharm, vol.73, issue.2, pp.239-246, 2009.

E. Moysan, G. Bastiat, and J. Benoit, Gemcitabine versus modified gemcitabine: a review of several promising chemical modifications, Mol Pharm, vol.10, issue.2, pp.430-444, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-00787112

A. M. Bergman, C. M. Kuiper, and D. A. Voorn, Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell lines, Biochem Pharmacol, vol.67, issue.3, pp.503-511, 2004.

A. M. Bergman, A. D. Adema, and J. Balzarini, Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models, Invest New Drugs, vol.29, issue.3, pp.456-466, 2011.

T. Qin, J. Jelinek, J. Si, J. Shu, and J. Issa, Mechanisms of resistance to 5-aza-2?-deoxycytidine in human cancer cell lines, Blood, vol.113, issue.3, pp.659-667, 2009.

J. Issa, G. Roboz, and D. Rizzieri, Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study, Lancet Oncol, vol.16, issue.9, pp.1099-1110, 2015.

B. Saliou, O. Thomas, and N. Lautram, Development and in vitro evaluation of a novel lipid nanocapsule formulation of etoposide

, Eur J Pharm Sci, vol.50, issue.2, pp.172-180, 2013.

E. Roger, F. Lagarce, and J. Benoit, Development and characterization of a novel lipid nanocapsule formulation of SN38 for oral administration, Eur J Pharm Biopharm, vol.79, issue.1, pp.181-188, 2011.

Y. R. Neupane, M. Srivastava, N. Ahmad, N. Kumar, A. Bhatnagar et al., Lipid based nanocarrier system for the potential oral delivery of decitabine: formulation design, characterization, ex vivo, and in vivo assessment, Int J Pharm, vol.477, issue.1-2, pp.601-612, 2014.

C. Dulieu and D. Bazile, Influence of lipid nanocapsules composition on their aptness to freeze-drying, Pharm Res, vol.22, issue.2, pp.285-292, 2005.

W. Tao, D. Zhao, and M. Sun, Intestinal absorption and activation of decitabine amino acid ester prodrugs mediated by peptide transporter PEPT1 and enterocyte enzymes, Int J Pharm, vol.541, issue.1-2, pp.64-71, 2018.

Y. Zhang, J. Sun, and Y. Gao, A carrier-mediated prodrug approach to improve the oral absorption of antileukemic drug decitabine, Mol Pharm, vol.10, issue.8, pp.3195-3202, 2013.

C. L. Clouser, L. Bonnac, L. M. Mansky, and S. E. Patterson, Characterization of permeability, stability and anti-HIV-1 activity of decitabine and gemcitabine divalerate prodrugs, Antivir Chem Chemother, vol.23, issue.6, pp.223-230, 2014.

G. Garcia-manero, O. Odenike, and P. C. Amrein, Successful emulation of IV decitabine pharmacokinetics with an oral Fixed-dose combination of the oral cytidine deaminase inhibitor (CDAi) E7727 with oral decitabine, in subjects with myelodysplastic syndromes (MDS): final data of phase 1 study, Am Soc Hematology, 2016.

D. Lavelle, K. Vaitkus, and Y. Ling, Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine, Blood, vol.119, issue.5, pp.1240-1247, 2012.

B. R. Sloat, M. A. Sandoval, and D. Li, In vitro and in vivo anti-tumor activities of a gemcitabine derivative carried by nanoparticles, Int J Pharm, vol.409, issue.1-2, pp.278-288, 2011.

A. Lainé, . Clavreula, and . Rousseaua, Inhibition of ectopic glioma tumor growth by a potent ferrocenyl drug loaded into stealth lipid nanocapsules, Nanomedicine, vol.10, issue.8, pp.1667-1677, 2014.

A. Paillard, F. Hindré, C. Vignes-colombeix, J. Benoit, and E. Garcion, The importance of endo-lysosomal escape with lipid nanocapsules for drug subcellular bioavailability, Biomaterials, vol.31, issue.29, pp.7542-7554, 2010.

P. W. Hollenbach, A. N. Nguyen, and H. Brady, A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines, PLoS One, vol.5, issue.2, p.9001, 2010.

S. Vijayaraghavalu, J. K. Dermawan, V. Cheriyath, and V. Labhasetwar, Highly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2/M cycle arrest, Mol Pharm, vol.10, issue.1, pp.337-352, 2013.

S. Thépot, L. E. Cluzeau, and T. , Hypomethylating agents reactivate FOXO3a in acute myeloid leukemia, Cell Cycle, vol.10, issue.14, pp.2323-2330, 2011.

Z. Liu, G. Marcucci, J. C. Byrd, M. Grever, J. Xiao et al., Characterization of decomposition products and preclinical and low dose clinical pharmacokinetics of decitabine (5-aza-2?-deoxycytidine) by a new liquid chromatography/tandem mass spectrometry quantification method, Rapid Commun Mass Spectrom, vol.20, issue.7, pp.1117-1126, 2006.

H. Xu, S. Lv, and M. Qiao, Development and validation of a liquid chromatography-tandem mass spectrometry method for quantification of decitabine in rat plasma, Journal of Chromatography B, vol.899, pp.81-85, 2012.

M. S. Sasso, G. Lollo, and M. Pitorre, Low dose gemcitabine-loaded lipid nanocapsules target monocytic myeloid-derived suppressor cells and potentiate cancer immunotherapy, Biomaterials, vol.96, pp.47-62, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01392469

A. Lainé, J. Gravier, and M. Henry, Conventional versus stealth lipid nanoparticles: formulation and in vivo fate prediction through FRET monitoring, J Control Release, vol.188, pp.1-8, 2014.

A. C. Groo, M. Bossiere, L. Trichard, P. Legras, J. P. Benoit et al., In vivo evaluation of paclitaxel-loaded lipid nanocapsules after intravenous and oral administration on resistant tumor, Nanomedicine, vol.10, issue.4, pp.589-601, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01153494

, International Journal of Nanomedicine, vol.50, issue.24, 2020.